6:16 PM
 | 
Jan 22, 2013
 |  BC Extra  |  Company News

Complete response for Impax's Parkinson's compound

Impax Laboratories Inc. (NASDAQ:IPXL) said FDA issued a complete response letter for an NDA for Rytary extended-release carbidopa/levodopa to treat idiopathic Parkinson's disease (PD). According to the...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >